133 related articles for article (PubMed ID: 17237293)
1. Modulation of topoisomerase IIalpha expression by a DNA sequence-specific polyamide.
Hochhauser D; Kotecha M; O'hare C; Morris PJ; Hartley JM; Taherbhai Z; Harris D; Forni C; Mantovani R; Lee M; Hartley JA
Mol Cancer Ther; 2007 Jan; 6(1):346-54. PubMed ID: 17237293
[TBL] [Abstract][Full Text] [Related]
2. Modulation of topoisomerase IIα expression and chemosensitivity through targeted inhibition of NF-Y:DNA binding by a diamino p-anisyl-benzimidazole (Hx) polyamide.
Pett L; Kiakos K; Satam V; Patil P; Laughlin-Toth S; Gregory M; Bowerman M; Olson K; Savagian M; Lee M; Lee M; Wilson WD; Hochhauser D; Hartley JA
Biochim Biophys Acta Gene Regul Mech; 2017 May; 1860(5):617-629. PubMed ID: 27750031
[TBL] [Abstract][Full Text] [Related]
3. Nuclear Localization and Gene Expression Modulation by a Fluorescent Sequence-Selective p-Anisyl-benzimidazolecarboxamido Imidazole-Pyrrole Polyamide.
Kiakos K; Pett L; Satam V; Patil P; Hochhauser D; Lee M; Hartley JA
Chem Biol; 2015 Jul; 22(7):862-75. PubMed ID: 26119998
[TBL] [Abstract][Full Text] [Related]
4. Nuclear factor-Y binding to the topoisomerase IIalpha promoter is inhibited by both the p53 tumor suppressor and anticancer drugs.
Joshi AA; Wu Z; Reed RF; Suttle DP
Mol Pharmacol; 2003 Feb; 63(2):359-67. PubMed ID: 12527807
[TBL] [Abstract][Full Text] [Related]
5. Targeting the inverted CCAAT box 2 in the topoisomerase IIalpha promoter by JH-37, an imidazole-pyrrole polyamide hairpin: design, synthesis, molecular biology, and biophysical studies.
Henry JA; Le NM; Nguyen B; Howard CM; Bailey SL; Horick SM; Buchmueller KL; Kotecha M; Hochhauser D; Hartley JA; Wilson WD; Lee M
Biochemistry; 2004 Sep; 43(38):12249-57. PubMed ID: 15379563
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78.
Kotecha M; Kluza J; Wells G; O'Hare CC; Forni C; Mantovani R; Howard PW; Morris P; Thurston DE; Hartley JA; Hochhauser D
Mol Cancer Ther; 2008 May; 7(5):1319-28. PubMed ID: 18483319
[TBL] [Abstract][Full Text] [Related]
7. Decreased topoisomerase IIα expression and altered histone and regulatory factors of topoisomerase IIα promoter in patients with chronic benzene poisoning.
Yu K; Shi YF; Yang KY; Zhuang Y; Zhu RH; Xu X; Cai G
Toxicol Lett; 2011 Jun; 203(2):111-7. PubMed ID: 21382456
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: a potential chemotherapeutic target.
Washiro M; Ohtsuka M; Kimura F; Shimizu H; Yoshidome H; Sugimoto T; Seki N; Miyazaki M
J Cancer Res Clin Oncol; 2008 Jul; 134(7):793-801. PubMed ID: 18204862
[TBL] [Abstract][Full Text] [Related]
9. Cell-cycle regulation of the DNA topoisomerase IIalpha promoter is mediated by proximal CCAAT boxes: possible involvement of acetylation.
Adachi N; Nomoto M; Kohno K; Koyama H
Gene; 2000 Mar; 245(1):49-57. PubMed ID: 10713444
[TBL] [Abstract][Full Text] [Related]
10. HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalpha.
Stros M; Polanská E; Struncová S; Pospísilová S
Nucleic Acids Res; 2009 Apr; 37(7):2070-86. PubMed ID: 19223331
[TBL] [Abstract][Full Text] [Related]
11. ATF is important to late S phase-dependent regulation of DNA topoisomerase IIalpha gene expression in HeLa cells.
Son MY; Kim TJ; Kweon KI; Park JI; Park C; Lee YC; No Z; Ahn JW; Yoon WH; Park SK; Lim K; Hwang BD
Cancer Lett; 2002 Oct; 184(1):81-8. PubMed ID: 12104051
[TBL] [Abstract][Full Text] [Related]
12. UPR-induced resistance to etoposide is downstream of PERK and independent of changes in topoisomerase IIα levels.
Mann MJ; Pereira ER; Liao N; Hendershot LM
PLoS One; 2012; 7(10):e47931. PubMed ID: 23144714
[TBL] [Abstract][Full Text] [Related]
13. Targeting the inverted CCAAT Box-2 of the topoisomerase IIalpha gene: DNA sequence selective recognition by a polyamide-intercalator as a staggered dimer.
Mackay H; Brown T; Sexton JS; Kotecha M; Nguyen B; Wilson WD; Kluza J; Savic B; O'Hare C; Hochhauser D; Lee M; Hartley JA
Bioorg Med Chem; 2008 Feb; 16(4):2093-102. PubMed ID: 17977733
[TBL] [Abstract][Full Text] [Related]
14. CBF/NF-Y functions both in nucleosomal disruption and transcription activation of the chromatin-assembled topoisomerase IIalpha promoter. Transcription activation by CBF/NF-Y in chromatin is dependent on the promoter structure.
Coustry F; Hu Q; de Crombrugghe B; Maity SN
J Biol Chem; 2001 Nov; 276(44):40621-30. PubMed ID: 11514576
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
Zhou Z; Zwelling LA; Kawakami Y; An T; Kobayashi K; Herzog C; Kleinerman ES
Cancer Res; 1999 Sep; 59(18):4618-24. PubMed ID: 10493516
[TBL] [Abstract][Full Text] [Related]
16. The effects of 1,4-benzoquinone on c-Myb and topoisomerase II in K-562 cells.
Singh R; Winn LM
Mutat Res; 2008 Oct; 645(1-2):33-8. PubMed ID: 18778717
[TBL] [Abstract][Full Text] [Related]
17. Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
Bhosle J; Kiakos K; Porter AC; Wu J; Makris A; Hartley JA; Hochhauser D
Mol Cancer Ther; 2013 Dec; 12(12):2897-908. PubMed ID: 24092808
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions.
Williams AO; Isaacs RJ; Stowell KM
BMC Mol Biol; 2007 May; 8():36. PubMed ID: 17511886
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional regulation of topoisomerase II alpha at confluence and pharmacological modulation of expression by bis-benzimidazole drugs.
Tolner B; Hartley JA; Hochhauser D
Mol Pharmacol; 2001 Apr; 59(4):699-706. PubMed ID: 11259613
[TBL] [Abstract][Full Text] [Related]
20. Altered expression of topoisomerase IIalpha contributes to cross-resistant to etoposide K562/MX2 cell line by aberrant methylation.
Asano T; Nakamura K; Fujii H; Horichi N; Ohmori T; Hasegawa K; Isoe T; Adachi M; Otake N; Fukunaga Y
Br J Cancer; 2005 Apr; 92(8):1486-92. PubMed ID: 15798770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
